Event Participants
Executives
2 Badri (Managing Director & Group CEO), Vikesh Kumar (Group CFO)
Analysts
10 Anand Mundra (Swar Wealth), Anupam Jain (Perception Investing), Gautami Aggarwal (Investor), Jinesh Shah (Investor), Kiran (Pavel Tree), Parth Sharda (Trinidra Asset Manager), Pratik Kothari (Unique PMS), Rupesh Tatya (Longbird Partners), Shilpa (Lotus Wealth), Yogesh Soni (Haitong Securities)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Total Revenue | ₹1,215.7 crores (U.S. ₹628.2 cr + Ex-U.S. ₹587.5 cr) | +13% YoY, broad-based contributions across segments; ex-U.S. (+17% YoY) outpaced company average |
| U.S. Revenue | ₹628.2 crores ($68M) | Stable YoY despite increased competition in recently launched products; launched 2 products (72 total), top-3 positions in 37 products (~70% of revenue); H2 expected much stronger |
| Ex-U.S. Revenue | ₹587.5 crores ($63M) | +17% YoY; QoQ down from $70M (Q4 FY26) due to supply-chain shipping delays (~$7M, timing not demand), recovery expected in coming quarters |
| Gross Margin | 60.9% | +60 bps YoY, driven by favorable ex-U.S. mix; absolute gross profit ₹770 crores, +14% YoY; management retains 58%-60% guidance range |
| EBITDA | ₹230 crores | +5.4% YoY; margin 18.2% (-130 bps YoY, slightly ahead of Q4 FY26's 18.1%); absorbed ₹13.1 crores of incremental geopolitical freight/operating costs |
| Operational PAT | ₹123 crores | +8% YoY; EBITDA-to-operational PAT conversion steady at 54% |
| Reported PAT | ₹166 crores | +57% YoY; includes ₹74 crores gain (₹53 crores net of tax) from Pivot Path divestment |
| EPS (Operational / Reported) | ₹13.4 / ₹17.0 per share | Operational EPS +8% YoY; reported EPS +57% YoY |
| Net Debt | ₹1,425 crores | Reduced ₹12 crores in quarter; Net debt/EBITDA improved to 1.52x from 1.55x (Mar FY26); excludes OneSource stake valued at ₹320 crores |
| Operating Cash Flow | ₹109 crores | EBITDA-to-cash conversion 47%; working capital absorbed by inventory build for supply-chain resilience |
| Cash-to-Cash Cycle | 123 days | +7 days YoY; inventory days +24, payable days +15 |
| Freight Costs | 6.2% of revenue | vs 5.3% a year ago (+18.9%); sequential improvement in cost lines during the quarter |
| Net Finance Cost | ₹36.1 crores | vs ₹40.6 crores in Q1 FY26; weighted avg cost of debt ~7.6% |
| RoCE (TTM) | 15.3% | vs 15.8% in FY26, as capital employed grew on recent investments/currency; expected to improve as investments mature |
Geographic & Segment Commentary
United States: Revenue of $68 million was stable despite increased competition; strategy prioritizes profitability and portfolio quality over growth at any cost. Launched 2 products (portfolio now 72), with top-3 positions in 37 products contributing ~70% of revenue. H2 FY27 is expected to be much stronger, supported by ~10 planned launches by March, controlled substances quota progression, and new approvals; ~1/3 of U.S. revenue is now supplied from the Chestnut Ridge facility, with all key growth platforms (controlled substances, nasal sprays, transdermal patches, films) anchored there.
Ex-U.S. (overall): Revenue grew 17% YoY to ₹587.5 crores ($63M); QoQ decline from $70M reflects shipping delays from supply-chain disruptions — a timing issue, not demand. Management reiterated that ex-U.S. will grow faster than the company average over the foreseeable future and is an increasing earnings contributor; the Sandoz acquisition (not yet closed) will add from H2 FY27.
Europe / UK / Nordics: U.K. prescription business delivered a strong performance through consistent supply and execution; branded and OTC portfolios across Europe and the Nordics posted strong quarterly results driven by portfolio expansion, customer additions, and improved market penetration.
Africa: Delivered another strong quarter, led by continued expansion of the branded business across Francophone Africa and Kenya.
Emerging Markets (LATAM, MENA, APAC): Regulatory filings are in progress; meaningful revenue build-out is expected from 2028-2029, with portfolio optimization and go-to-market efforts underway. B2B markets (Europe, Australia) provide stability to the B2C mix.
Company-Specific & Strategic Commentary
Diversification strategy: Ex-U.S. growth of 17% YoY validates the multi-geography model built over the last few years; management expects ex-U.S. to remain a primary driver of both growth and earnings.
U.S. specialty platforms: Controlled substances (4 products, ~20 months of demonstrated sales history, ~5% of U.S. revenue) are positioned for faster ramp from years 2-4; nasal spray pipeline progressing (first approval expected Q3/Q4 FY27, second filed with 12-15 month review, third filing imminent; 5-6 programs) alongside transdermal patches and films — these anchor growth beyond the $375M aspiration.
U.S. onshoring / tariff mitigation: Nearly one-third of U.S. revenue is supplied from the Chestnut Ridge U.S. facility; all key growth platforms are being developed around this network, providing a balanced model against proposed U.S. tariffs on generics from August 2028.
Pivot Path divestment: Sold majority stake in the captive global capability center for ~₹100 crores, booking a ₹74 crores gain (₹53 crores net to reported PAT); the third-party business is expected to add to group PAT over 4-5 years.
Rating & ESG: CARE Ratings upgraded long-term bank facilities to CARE A+ Stable from CARE A Positive; EcoVadis score improved 19 points YoY to 68/100.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| U.S. Revenue | H2 FY27 much stronger; $375M North America aspiration for FY28 (from $284M FY26 base) | ~10 launches by Mar FY27 and significantly more next year; five levers: controlled substances, new channels, new geographies/partnerships, launches (100+ products in inventory), OTC portfolio; full impact expected in FY28 |
| Ex-U.S. Growth | Faster than company average over foreseeable future; Sandoz acquisition closes Q2 FY27, contributing from H2 | Q1 ~$7M supply-chain gap is timing-related; underlying demand healthy; investments in markets/partnerships/portfolio continue to mature |
| Gross Margin | 58%-60% range maintained | Q1 actual 60.9% on favorable ex-U.S. mix; focus on portfolio quality and cost optimization |
| Net Debt | Fairly neutral in 2-3 years | ~₹3 billion of debt reduced last year but INR depreciation (₹82→₹95-97) masked the reduction in INR terms; continued focus on net debt/EBITDA |
| CapEx + R&D Spend | ₹250-300 crores per annum | Combination of maintenance CapEx, R&D, and hard CapEx; no greenfield projects; capital deployed on high-impact line items |
| Sandoz Acquisition | Close in Q2 FY27, subject to permissions | Not reflected in Q1 FY27 numbers; P&L accretion expected from H2 FY27 |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical / supply chain | Ongoing conflict continues to cause supply-chain disruptions, elevated trade/freight costs, longer transit times, and inflation. Q1 absorbed ₹13.1 crores of incremental costs; freight at 6.2% of revenue (vs 5.3% YoY); ~$7M of ex-U.S. shipments delayed. Management is proactively managing supply continuity and expects recovery over coming quarters. |
| U.S. tariffs (August 2028) | Proposed tariffs on generic pharmaceutical products have limited visibility on the final implementation framework. Mitigation rests on the Chestnut Ridge U.S. facility supplying ~1/3 of U.S. sales, with growth platforms (controlled substances, nasal sprays, transdermal, films) being onshored; management believes the model is fairly balanced. |
| Controlled substances quota | Quota allocations happen twice a year (June/December) based on demonstrated past sales; the June cycle response is pending (expected next month). Ramp-up has been slower than expected — CS is ~5% of U.S. revenue — but 20 months of demonstrated history should support higher quotas in subsequent cycles. |
| Regulatory (Bangalore USFDA) | USFDA inspection of the Bangalore plant occurred in May; a comprehensive response was submitted, with a reply expected by end-August/September. No impact on current supplies or U.S. growth aspirations is anticipated, but the outcome remains a watch item. |
| U.S. competitive intensity | Increased competition in products launched over recent quarters has pressured U.S. revenue; the company is prioritizing profitability and portfolio quality over growth, which defers volume upside. |
| Working capital build | Cash-to-cash cycle extended to 123 days (+7 days YoY) on a 24-day inventory build for supply-chain resilience; absolute working capital requirement increased, driving EBITDA-to-cash conversion down to 47% in Q1. |
| Currency / debt optics | INR depreciation from ~₹82 to ₹95-97 inflates INR-denominated net debt despite ~₹3 billion of actual debt reduction last year; net debt of ₹1,425 crores is expected to normalize in 2-3 years. |
Q&A Highlights
U.S. path to $375 million
- Question: U.S. has been soft for several quarters despite competition commentary; what levers bridge the gap from a $284M FY26 base to the FY28 target? (Pratik Kothari, Unique PMS; Gautami Aggarwal, Investor)
- Answer: Q1-Q2 will remain soft, with the bulk of launches from H2 onwards. Five levers are being executed: controlled substances (past history demonstrated over ~2 years), new channels, new geographies/partnerships (Canada discussions underway), product launches (100+ unlaunched products, released systematically from Q2), and the OTC portfolio. Management declined to quantify dollar contribution per lever but reaffirmed the groundwork is complete. (Badri)
Net debt trajectory
- Question: Given accelerated investments, what is the path to becoming net debt-free? (Pratik Kothari, Unique PMS)
- Answer: Net debt stands at ~₹1,420-1,425 crores, excluding the OneSource stake valued at ₹320 crores. The company reduced ~₹3 billion of debt last year, but INR depreciation (₹82→₹95-97) masked the reduction in INR terms; expect to be fairly debt-neutral in 2-3 years. (Badri)
Ex-U.S. cyclicality and Sandoz
- Question: Ex-U.S. revenue fell from $70M (Q4) to $63M (Q1); is this cyclical, and does it include the Sandoz acquisition? (Kiran, Pavel Tree)
- Answer: The QoQ decline is a timing issue from shipping delays and geopolitical logistics, not demand; the ~$7M gap will be recovered in coming quarters. The Sandoz acquisition is not in Q1 numbers; closing is expected in Q2 FY27 pending permissions, with contribution from H2. (Badri)
Pivot Path divestment
- Question: Pivot Path had ~₹144 crores revenue; is a ~₹125 crores valuation (<1x sales) justified? (Kiran, Pavel Tree)
- Answer: The deal should not be viewed on a standalone sales multiple. Pivot Path has both captive and third-party businesses and is not significant to Strides' revenue; the third-party business is expected to scale and add to group PAT over 4-5 years. (Badri)
Funding cost and debt mix
- Question: What is the weighted cost of debt and its composition? (Anupam Jain, Perception Investing)
- Answer: Weighted average cost of debt is ~7.6%, with debt aligned across geographies (predominantly India and the U.S.); interest costs have reduced consistently over the last 7-8 quarters. The CARE rating covers only specific long-term loan categories, not the entire debt book. (Vikesh Kumar)
Nasal spray pipeline
- Question: What is the FDA review status of the two nasal spray filings and expected approval timing? (Yogesh Soni, Haitong Securities)
- Answer: The first nasal spray is at an advanced review stage with approval expected in Q3/Q4 FY27 (timing can shift month to month). The second was filed ~1 month ago with a 12-15 month review cycle. There are 5-6 nasal programs active, similar scale in transdermal patches and films, and a third nasal filing is expected in the next few months; these platforms will drive growth beyond the $375M target. (Badri)
Launch cadence and quality
- Question: How many launches are planned this year, and will they skew toward larger-revenue molecules? (Rupesh Tatya, Longbird Partners)
- Answer: ~10 launches are planned by March 31, with significantly higher numbers next year. Launches are one of six levers to bridge the ~$80-90 million gap from $285M to $375M U.S. revenue, with full impact visible in FY28. Management did not specify per-molecule revenue thresholds. (Badri)
Controlled substances quotas
- Question: How do quota allocations work, and what has caused the delay? (Rupesh Tatya, Longbird Partners)
- Answer: Quota allocations occur twice a year (June and December) based on demonstrated past sales; new entrants need customer sponsorship (non-binding), making initial demonstration difficult. Strides has 4 CS products (~5% of U.S. revenue last year) with ~20 months of demonstrated history; ramp-ups typically accelerate in years 2-4, and the June cycle response is expected next month. (Badri)
CapEx plans
- Question: What are the brownfield/greenfield CapEx plans for the next two years? (Shilpa, Lotus Wealth)
- Answer: Annual spend is ₹250-300 crores, combining maintenance CapEx, R&D, and hard CapEx; there are no greenfield projects, with capital directed at high-impact line items within existing facilities. (Badri)
Bangalore USFDA inspection
- Question: What is the status of the Bangalore plant USFDA inspection and its impact on U.S. growth aspirations? (Jinesh Shah, Investor)
- Answer: The inspection occurred in May; a comprehensive response has been submitted, with a USFDA reply expected by end-August/September. There is no impact on current supplies and no anticipated impact on U.S. revenue aspirations over the next 4-5 quarters. (Badri)
Key Takeaway
Strides Pharma delivered a steady Q1 FY27: total revenue rose 13% YoY to ₹1,215.7 crores (U.S. $68M/₹628.2 crores; ex-U.S. ₹587.5 crores, +17% YoY) despite ₹13.1 crores of geopolitical freight and operating costs. Gross margin expanded 60 bps to 60.9%, EBITDA grew 5.4% to ₹230 crores (18.2% margin), and reported PAT jumped 57% to ₹166 crores, including ₹53 crores net gain from the Pivot Path divestment. Management reiterated the $375 million FY28 North America ambition, expecting U.S. acceleration in H2 FY27 from ~10 launches, controlled substances quota progression (June cycle response pending), and nasal spray approvals, with ~1/3 of U.S. revenue already supplied from the onshored Chestnut Ridge facility. Ex-U.S. is positioned to keep outpacing company growth, aided by the Sandoz acquisition closing in Q2 FY27. Key watch points: freight inflation, a 123-day cash cycle, the Bangalore USFDA inspection outcome (reply expected by August/September), and controlled substances quota ramp.